Showing 4001-4010 of 10490 results for "".
- Eczema Breakthrough: S. aureus Evolve to a Variant with a Mutation in a Specific Gene to Grow Fasterhttps://practicaldermatology.com/news/eczema-breakthrough-s-aureus-evolve-to-a-variant-with-a-mutation-in-a-specific-gene-to-grow-faster/2461659/New research shows how Staphylococcus aureus gains mutations that allow it to colonize eczema patches. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin. This study marks the first t
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cellshttps://practicaldermatology.com/news/20140407-presentation_pv-10_decreases_melanoma_cells_in_tumors_and_boosts_t-cells/2459277/Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Sa
- Serum adipokines and T-helper 17-related Cytokines Associated in Psoriasishttps://practicaldermatology.com/news/20121025-serum_adipokines_and_t-helper_17-related_cytokines_associated_in_psoriasis/2459692/New research suggests that adipokines and Th17 cytokines are involved in the pathogenesis of psoriasis. (Clin Exp Dermatol, E-pub) In patients with psoriasis, resistin levels were significantly positively associated with tumour necrosis factor-α, and there was a strong negative association between r
- FDA Clears DeepX Diagnostics Inc.'s DermoSight for Telederm Screening of Suspicious Lesionshttps://practicaldermatology.com/news/fda-clears-deepx-diagnostics-incs-dermosight-for-telederm-screening-of-suspicious-lesions/2461763/The US Food and Drug Administration (FDA) has cleared DeepX Diagnostics Inc.’s digital dermatoscope DermoSight for teledermatology screening of suspected skin cancer lesions. DermoSight is currently cle
- Coming Soon to a City Near You: Sciton Inc.'s Bright Lights Big City BBL 2018 Tourhttps://practicaldermatology.com/news/coming-soon-to-a-city-near-you-sciton-incs-bright-lights-big-city-bbl-2018-tour/2457815/Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in For
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- Leo Pharma's Adbry Reduces S. aureus Skin Colonization in Kids With ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-reduces-s-aureus-skin-colonization-in-kids-with-ad/2461616/Leo Pharma’s Adbry (tralokinumab-ldrm) significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with atopic dermatitis (AD) after 16 weeks, according to new data presented at the American Academy of Dermatology
- Two New Grants Continue Dr. Fredric S. Brandt's Legacyhttps://practicaldermatology.com/news/two-new-grants-continue-dr-fredric-s-brandts-legacy/2458018/Two American Society for Dermatologic Surgery members received grants totaling more tha
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw